en · de · es
creatine-notes.peptides8425.com › Info › Identity And Molecular Context — Beginner to Advanced

Identity And Molecular Context — Beginner to Advanced

By Editorial Desk · published 2025-07-26 · last reviewed 2025-09-15 · Info

storage stability comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-09-15. Numbers and descriptions here follow the published literature rather than marketing material.

Identity and Molecular Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.

The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.

Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideDerived from a fragment of human growth hormone
Sequence basishGH residues 176-191Commonly described as a 16-amino-acid fragment
AppearanceWhite to off-white powderTypical for lyophilized research peptides
SolubilitySoluble in water or aqueous bufferExact solubility depends on pH and purity
Common synonymsAOD9604; hGH 176-191Spelling and punctuation vary across sources

Research and Regulatory Context

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Background and Development History

AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.

Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.

Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.

Background from the literature

Lipid metabolism is the synthesis and degradation of lipids in cells, involving the breakdown and storage of fats for energy and the synthesis of structural and functional lipids, such as those involved in the construction of cell membranes. In animals, these fats are obtained from food and are synthesized by the liver. Lipogenesis is the process of synthesizing these fats. The majority of lipids found in the human body from ingesting food are triglycerides and cholesterol. Other types of lipids found in the body are fatty acids and membrane lipids. Lipid metabolism is often considered the digestion and absorption process of dietary fat; however, there are two sources of fats that organisms can use to obtain energy: from consumed dietary fats and from stored fat. Vertebrates (including humans) use both sources of fat to produce energy for organs such as the heart to function. Since lipids are hydrophobic molecules, they need to be solubilized before their metabolism can begin. Lipid metabolism often begins with hydrolysis, which occurs with the help of various enzymes in the digestive system. Lipid metabolism also occurs in plants, though the processes differ in some ways when compared to animals. The second step after the hydrolysis is the absorption of the fatty acids into the epithelial cells of the intestinal wall. In the epithelial cells, fatty acids are packaged and transported to the rest of the body. Metabolic processes include lipid digestion, lipid absorption, lipid transportation, lipid storage, lipid catabolism, and lipid biosynthesis.

The three substrates of this enzyme are trypanothione disulfide, reduced nicotinamide adenine dinucleotide phosphate (NADPH), and a proton. Its products are trypanothione and oxidised NADP+. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is trypanothione:NADP+ oxidoreductase. Other names in common use include trypanothione reductase, and NADPH2:trypanothione oxidoreductase. It employs one cofactor, FAD. The X-ray crystal structures of trypanothione reductase enzymes from several trypanosomatids species have been solved, including those from Crithidia fasciculata, Leishmania infantum, Trypanosoma brucei and Trypanosoma cruzi. The structures reveal that trypanothione reductase forms homodimers in solution with each of the two individual subunits comprising an flavin adenine dinucleotide-binding domain, an NADPH-binding domain and an interface domain. Examples of trypanothione reductase inhibitors include 5-nitroimidazole, febrifugine, imipramine and benzoxaborole.

=== Palmar and plantar aponeuroses and extensor hood === The palmar aponeuroses occur on the palms of the hands. The extensor hoods are aponeuroses at the back of the fingers. The plantar aponeuroses occur on the plantar aspect of the foot. They extend from the calcaneal tuberosity then diverge to connect to the bones, ligaments and the dermis of the skin around the distal part of the metatarsal bones.

== Early life, education and career == Roy was born in the Indian state of West Bengal. He completed his schooling at Ballygunge Government High School, then obtained a first class honours degree in chemistry (BSc Hons) from Presidency College, Calcutta in 1974 and did his doctoral studies at the University of Delaware under the guidance of Prof. Roberta F. Colman to secure a PhD in 1981. His post-doctoral studies were at Brandeis University at the laboratory of Prof. Alfred Redfield (1981–82) and at the National Institutes of Health (1982–86). Returning to India in 1986, he joined Bose Institute, Kolkata as a senior lecturer in the department of biophysics. He served the Institute till 2004 holding positions of Reader and then Professor of Biophysics when he moved to the Indian Institute of Chemical Biology (IICB) as its director. After completing 10 years as the director of IICB, he returned to Bose Institute in 2014 as a senior professor and dean of studies. While at IICB, he has served the nation in several different high-level capacities such as the founder-director-in-charge of the National Institute of Pharmaceutical Education and Research, Kolkata (NIPER) (2007–14), the cluster director of 11 Biological institutes of the Council of Scientific and Industrial Research (CSIR) (2009–14), member of the governing body of the CSIR and as a visiting professor at Osaka University (2012). He has served as the president of the West Bengal Academy of Science and Technology. He is the founder-president of the Chemical Biology Society of India.

Sources: en.wikipedia.org

Further detail

Originally this research on alternative forms of DNA was driven by the question of how life evolved on earth and why RNA and DNA were selected by (chemical) evolution over other possible nucleic acid structures. Two hypotheses for the selection of RNA and DNA as life's backbone are either they are favored under life on Earth's conditions, or they were coincidentally present in pre-life chemistry and continue to be used now. Systematic experimental studies aiming at the diversification of the chemical structure of nucleic acids have resulted in completely novel informational biopolymers. So far a number of XNAs with new chemical backbones or leaving group of the DNA have been synthesized, e.g.: hexose nucleic acid (HNA); threose nucleic acid (TNA), glycol nucleic acid (GNA) cyclohexenyl nucleic acid (CeNA). The incorporation of XNA in a plasmid, involving 3 HNA codons, has been accomplished already in 2003. This XNA is used in vivo (E coli) as template for DNA synthesis. This study, using a binary (G/T) genetic cassette and two non-DNA bases (Hx/U), was extended to CeNA, while GNA seems to be too alien at this moment for the natural biological system to be used as template for DNA synthesis. Extended bases using a natural DNA backbone could, likewise, be transliterated into natural DNA, although to a more limited extent. Aside being used as extensions to template DNA strands, XNA activity has been tested for use as genetic catalysts.

The antibody selectively binds to protein A/G, so a high level of purity (generally >80%) is obtained. The generally harsh conditions of this method may damage easily damaged antibodies. A low pH can break the bonds to remove the antibody from the column. In addition to possibly affecting the product, low pH can cause protein A/G itself to leak off the column and appear in the eluted sample. Gentle elution buffer systems that employ high salt concentrations are available to avoid exposing sensitive antibodies to low pH. Cost is also an important consideration with this method because immobilized protein A/G is a more expensive resin. To achieve maximum purity in a single step, affinity purification can be performed, using the antigen to provide specificity for the antibody. In this method, the antigen used to generate the antibody is covalently attached to an agarose support. If the antigen is a peptide, it is commonly synthesized with a terminal cysteine, which allows selective attachment to a carrier protein, such as KLH during development and to support purification. The antibody-containing medium is then incubated with the immobilized antigen, either in batch or as the antibody is passed through a column, where it selectively binds and can be retained while impurities are washed away. An elution with a low pH buffer or a more gentle, high salt elution buffer is then used to recover purified antibody from the support.

Tents Sleeping bags Storage food (usually dehydrated or freeze dried) with long shelf life Electrical generators First aid supplies MREs (meals ready to eat) Wind-up radios Wind-up flashlights Backpacks

Sources: en.wikipedia.org

Background from the literature

=== Custom Tags === ColdFusion provides several ways to implement custom markup language tags, i.e. those not included in the core ColdFusion language. These are especially useful for providing a familiar interface for web designers and content authors familiar with HTML but not imperative programming. The traditional and most common way is using CFML. A standard CFML page can be interpreted as a tag, with the tag name corresponding to the file name prefixed with "cf_". For example, the file IMAP.cfm can be used as the tag "cf_imap". Attributes used within the tag are available in the ATTRIBUTES scope of the tag implementation page. CFML pages are accessible in the same directory as the calling page, via a special directory in the ColdFusion web application, or via a CFIMPORT tag in the calling page. The latter method does not necessarily require the "cf_" prefix for the tag name. A second way is the developments of CFX tags using Java or C++. CFX tags are prefixed with "cfx_", for example "cfx_imap". Tags are added to the ColdFusion runtime environment using the ColdFusion administrator, where JAR or DLL files are registered as custom tags. Finally, ColdFusion supports JSP tag libraries from the JSP 2.0 language specification. JSP tags are included in CFML pages using the CFIMPORT tag.

== SO == so – (s) Somali language (ISO 639-1 code) SO (i) Shared Object (Unix) Sheriff's Office Significant other (s) Somalia (ISO 3166 and FIPS 10-4 country code digram) SOA (a) service-oriented architecture (a) Society of Actuaries (i) State of the art SOAP (a) Simple Object Access Protocol Supplemental Offer and Acceptance Program (U.S. medical residency matching) SOB (i) Son Of a Bitch Same Old Bullshit SOC – (a) Sector Operations Centre Soccsksargen – (p) South Cotabato, Cotabato, Sultan Kudarat, Sarangani, General Santos (a region in the Philippines; pronounced "sock-sar-gen") SOCOM – (p) (U.S.) Special Operations Command SoCon – (p) Southern Conference (U.S.

=== Symbiosis === Once the fungal hyphae make contact with root cap cells, they must continue to grow inwards to the epidermal cells and multiply to form the layers that will eventually produce the mantle. Production of the fungal mantle involves the upregulation of genes responsible for translation and cell growth, as well as those responsible for membrane synthesis and function, such as hydrophobins. Some polypeptides are only found when the fungus and plant have achieved symbiosis; these symbiosis-related (SR) proteins are termed ectomycorrhizins. Major changes in polypeptide and mRNA synthesis happen rapidly after colonization by the fungus, including the production of ectomycorrhizins. Changes include the upregulation of genes that may help new membranes to form at the symbiotic interface. The effect of the mantle on root proliferation, root hair development and dichotomous branching can be partially mimicked by fungal exudates, providing a path to identifying the molecules responsible for communication. The Hartig net initially forms from the fully differentiated inner layer of the mantle, and penetration occurs in a broad front oriented at right angles to the root axis, digesting through the apoplastic space. Some plant cells respond by producing stress- and defense-related proteins including chitinases and peroxidases that could inhibit Hartig net formation.

=== Natural sciences === Chemical reactions: The rates of certain types of chemical reactions depend on the concentration of one or another reactant. Reactions whose rate depends only on the concentration of one reactant (known as first-order reactions) consequently follow exponential decay. For instance, many enzyme-catalyzed reactions behave this way. Electrostatics: In a RC circuit, the electric charge (or, equivalently, the potential) contained in a capacitor (capacitance C) discharges through a constant external load (resistance R) with exponential decay and similarly charges with the mirror image of exponential decay (when the capacitor is charged from a constant voltage source though a constant resistance). The exponential time-constant for the process is

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 the same as human growth hormone?

No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.

What is the exact length of AOD-9604?

It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.

Does AOD-9604 occur naturally?

It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network